Susan M. O’Brien, MD | Authors

Potential Approvals of CLL Combination Therapies in 2022

December 31, 2021

Susan M. O’Brien, MD, on potential upcoming approvals in 2022 for treating chronic lymphocytic leukemia with combination therapies.

Looking Toward the New Trends in CLL

December 30, 2021

Susan M. O’Brien, MD, on upcoming 2022 trends in chronic lymphocytic leukemia treatment.

Importance of Clinical Trial Enrollment for CLL

December 29, 2021

Susan M. O’Brien, MD, on why clinical trial enrollment is so important for patients with chronic lymphocytic leukemia.

Ongoing Trials of Combination Therapy for Treating CLL

December 27, 2021

Susan M. O’Brien, MD, highlights ongoing trials from 2021 examining combination therapies for patients with chronic lymphocytic leukemia.

Novel Mechanisms of Action in Chronic Lymphocytic Leukemia

December 24, 2021

Susan M. O’Brien, MD, discusses novel mechanisms of action and BTK inhibitors for patients with chronic lymphocytic leukemia.

Adverse Effects of Concern When Treating Chronic Lymphocytic Leukemia

December 23, 2021

Susan M. O’Brien, MD, on common toxicities and adverse effects when treating patients with chronic lymphocytic leukemia.

Combination Therapies for Chronic Lymphocytic Leukemia

December 21, 2021

Susan M. O’Brien, MD, on combination therapies for treating patients with chronic lymphocytic leukemia.

BTK Inhibitors in the Presence of 17p Deletions or TP53 Mutation in CLL

December 19, 2021

Susan M. O’Brien, MD, on treating patients with 17p deletions and TP53 mutations who have chronic lymphocytic leukemia.

Approved BTK Inhibitors for Chronic Lymphocytic Leukemia

December 17, 2021

Susan M. O’Brien, MD, on the approved BTK inhibitors for treating chronic lymphocytic leukemia.

Noncovalent BTK Inhibitors for Chronic Lymphocytic Leukemia

December 15, 2021

Susan M. O’Brien, MD, discussed the emergence of noncovalent BTK inhibitors for treating chronic lymphocytic leukemia.